Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

J. Cortés Castán, Peter Schmid(Queen Mary University of London), Ahmad Awada(Institut Jules Bordet), Hardeep Uppal, IC Tudor, Martha Blaney, Joyce Steinberg(Astellas Pharma (United States)), Denise A. Yardley(Sarah Cannon), Clifford A. Hudis(Memorial Sloan Kettering Cancer Center), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
May 1, 2015
10.1093/annonc/mdv115.01
Cited by 16Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis